Unpredictability of intravenous busulfan pharmacokinetics in children undergoing hematopoietic stem cell transplantation for advanced beta thalassemia: limited toxicity with a dose-adjustment policy.

[1]  S. Corbacioglu.  The Prospective Study on the Incidence and Outcome of VOD with the Prophylactic Use of Defibrotide in Pediatric Stem Cell Transplantation has completed enrolment: Update on the VOD-DF Study , 2009 .

[2]  C. Knibbe,et al.  Association between busulfan exposure and outcome in children receiving intravenous busulfan before hematologic stem cell transplantation. , 2009, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[3]  A. Mastronuzzi,et al.  Treosulfan‐based conditioning regimen for allogeneic haematopoietic stem cell transplantation in patients with thalassaemia major , 2008, British journal of haematology.

[4]  Xinjing Wang,et al.  Glutathione S‐Transferase A1 Genetic Variants Reduce Busulfan Clearance in Children Undergoing Hematopoietic Cell Transplantation , 2008, Journal of clinical pharmacology.

[5]  M. Roncarolo,et al.  Second hematopoietic SCT in patients with thalassemia recurrence following rejection of the first graft , 2008, Bone Marrow Transplantation.

[6]  P. Shaw,et al.  Variability in the pharmacokinetics of intravenous busulphan given as a single daily dose to paediatric blood or marrow transplant recipients. , 2008, British journal of clinical pharmacology.

[7]  S. Santarone,et al.  Long‐term results of survival in patients with thalassemia major treated with bone marrow transplantation , 2008, American journal of hematology.

[8]  Matthew Darlison,et al.  Global epidemiology of haemoglobin disorders and derived service indicators. , 2008, Bulletin of the World Health Organization.

[9]  M. Ansari,et al.  IV busulfan dose individualization in children undergoing hematopoietic stem cell transplant: limited sampling strategies. , 2008, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[10]  G. Lucarelli,et al.  Advances in the allogeneic transplantation for thalassemia. , 2008, Blood reviews.

[11]  A. L. Maître,et al.  Elevated Plasma Ferritin and Busulfan Pharmacodynamics During High‐dose Chemotherapy Regimens in Children with Malignant Solid Tumors , 2007, Clinical pharmacology and therapeutics.

[12]  G. Vassal,et al.  Prospective validation of a novel IV busulfan fixed dosing for paediatric patients to improve therapeutic AUC targeting without drug monitoring , 2007, Cancer Chemotherapy and Pharmacology.

[13]  L. Dupuis,et al.  Pharmacokinetic disposition and clinical outcomes in infants and children receiving intravenous busulfan for allogeneic hematopoietic stem cell transplantation. , 2007, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[14]  A. Pession,et al.  Unrelated Bone Marrow Transplantation for β‐Thalassemia Patients: The Experience of the Italian Bone Marrow Transplant Group , 2005, Annals of the New York Academy of Sciences.

[15]  A. Cnaan,et al.  Survival and Complications in Thalassemia , 2005, Annals of the New York Academy of Sciences.

[16]  M. Andreani,et al.  New approach for bone marrow transplantation in patients with class 3 thalassemia aged younger than 17 years. , 2004, Blood.

[17]  L. Nguyen,et al.  I.V. busulfan in pediatrics: a novel dosing to improve safety/efficacy for hematopoietic progenitor cell transplantation recipients , 2004, Bone Marrow Transplantation.

[18]  P. Amrolia,et al.  Bone marrow transplantation for β‐thalassaemia major: the UK experience in two paediatric centres , 2003, British journal of haematology.

[19]  B. Green,et al.  Effect of polymorphism in the human glutathione S-transferase A1 promoter on hepatic GSTA1 and GSTA2 expression. , 2001, Pharmacogenetics.

[20]  P. Ljungman,et al.  Population pharmacokinetic analysis resulting in a tool for dose individualization of busulphan in bone marrow transplantation recipients , 2001, Bone Marrow Transplantation.

[21]  M. Chandy,et al.  Glutathione S-transferase activity influences busulfan pharmacokinetics in patients with beta thalassemia major undergoing bone marrow transplantation. , 2001, Drug metabolism and disposition: the biological fate of chemicals.

[22]  B. Bostrom,et al.  Relationship of plasma pharmacokinetics of high-dose oral busulfan to the outcome of allogeneic bone marrow transplantation in children with thalassemia , 1997, Bone Marrow Transplantation.

[23]  F. Appelbaum,et al.  Graft-rejection and toxicity following bone marrow transplantation in relation to busulfan pharmacokinetics. , 1995, Bone marrow transplantation.

[24]  M. Andreani,et al.  Marrow transplantation in patients with thalassemia responsive to iron chelation therapy. , 1993, The New England journal of medicine.

[25]  T. Shea,et al.  Measurement of busulfan in plasma by high-performance liquid chromatography. , 1987, Journal of chromatography.